Sodium Tetradecyl Sulfate
Sodium tetradecyl sulfate is a detergent-class sclerosing agent used for the treatment of varicose veins and hemorrhoids by injecting directly into the vessel lumen, causing endothelial damage, thrombosis, and subsequent fibrosis to obliterate the vein. By disrupting the endothelial cell lipid bilayer, it triggers an inflammatory response leading to sclerosis and permanent closure of the target vessel. It is used in sclerotherapy as an alternative to surgical vein stripping.
Masse moléculaire
316,4300 g/mol
TPSA
74,80 Ų
Aires thérapeutiques
Mécanisme d'action
Causes endothelial damage and inflammation when injected into a vessel, leading to thrombosis, fibrosis, and eventual obliteration of the treated vein or vascular malformation.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Causes endothelial damage and inflammation when injected into a vessel, leading to thrombosis, fibrosis, and eventual obliteration of the treated vein or vascular malformation.
Structure 2D
Cite this structure
Embed this structure
SMILES
CCCCC(CC)CCC(CC(C)C)OS(=O)(=O)[O-].[Na+]
InChI
InChI=1S/C14H30O4S.Na/c1-5-7-8-13(6-2)9-10-14(11-12(3)4)18-19(15,16)17;/h12-14H,5-11H2,1-4H3,(H,15,16,17);/q;+1/p-1
Molecular Formula
C14H29NaO4S
HBD / HBA
- / 4
Liaisons Rotatives
11
Atomes Lourds
20
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Foire aux questions
Sodium tetradecyl sulfate is a detergent-class sclerosing agent used for the treatment of varicose veins and hemorrhoids by injecting directly into the vessel lumen, causing endothelial damage, thrombosis, and subsequent fibrosis to obliterate the vein. By disrupting the endothelial cell lipid bilayer, it triggers an inflammatory response leading to sclerosis and permanent closure of the target vessel. It is used in sclerotherapy as an alternative to surgical vein stripping.
Causes endothelial damage and inflammation when injected into a vessel, leading to thrombosis, fibrosis, and eventual obliteration of the treated vein or vascular malformation.
Yes, Sodium Tetradecyl Sulfate is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1200354. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 23665772. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="sodium-tetradecyl-sulfate"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/sodium-tetradecyl-sulfate/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/sodium-tetradecyl-sulfate/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/sodium-tetradecyl-sulfate/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="sodium-tetradecyl-sulfate"></drugfyi-drug>